RESUMEN
BACKGROUND Percutaneous transvenous lead extraction (TLE) of cardiac implantable electronic devices can be performed with a high success rate. However, TLE has its limitations and challenges. Recognizing the challenges at an early stage during the procedure is vital for appropriate patient management. We present a challenging case of implantable cardioverter-defibrillator (ICD) lead extraction in which we aborted TLE in favor of elective surgical extraction (SE). This potentially prevented a major catastrophic complication of vascular tear, which would have required an emergent thoracotomy. CASE REPORT A 37-year-old woman with history of hypertrophic cardiomyopathy had a primary prevention dual-chamber ICD implant in 2001 and underwent right ventricular ICD lead revision in 2009 due to lead fracture. In 2019, she was again found to have right ventricular ICD lead malfunction. TLE was attempted, but no meaningful progression could be made despite using multiple extraction tools. Therefore, TLE was aborted in favor of SE. During elective SE, significant adhesions were noted, and the innominate vein was completely avulsed during removal of the leads, requiring venous reconstruction by the vascular surgery team. After SE and vascular reconstruction, an epicardial ICD system was placed, and the patient had an uneventful postoperative recovery. CONCLUSIONS This case report highlights the limitations of TLE and the importance of recognizing them in a timely manner. In all challenging cases, conversion to elective SE should be considered to avoid potential injuries warranting emergent surgical repair.
Asunto(s)
Cardiomiopatía Hipertrófica , Desfibriladores Implantables , Adulto , Cardiomiopatía Hipertrófica/complicaciones , Cardiomiopatía Hipertrófica/terapia , Desfibriladores Implantables/efectos adversos , Remoción de Dispositivos , Femenino , Humanos , Adherencias Tisulares , Resultado del TratamientoRESUMEN
BACKGROUND: Spontaneous coronary artery dissection (SCAD) is an under-recognized cause of acute coronary syndrome in women. CASE PRESENTATION: We present a 40-year-old female who presented with recurrent STEMI due to recurrent SCAD 10 days after the index presentation in a different coronary territory. She was successfully treated both times with drug eluting stents. MRI showed an evidence of transmural infarction but her ejection fraction was only mildly reduced. She had good short term outcome. CONCLUSION: High index of suspicion is crucial for early diagnosis and prompt medical and interventional management in patients with SCAD.
Asunto(s)
Anomalías de los Vasos Coronarios , Intervención Coronaria Percutánea , Infarto del Miocardio con Elevación del ST , Enfermedades Vasculares , Adulto , Angiografía Coronaria , Anomalías de los Vasos Coronarios/diagnóstico , Anomalías de los Vasos Coronarios/diagnóstico por imagen , Disección , Femenino , Humanos , Recurrencia , Infarto del Miocardio con Elevación del ST/diagnóstico por imagen , Infarto del Miocardio con Elevación del ST/etiología , Enfermedades Vasculares/diagnóstico por imagenRESUMEN
One of the dreaded complications of left ventricular assist device implantation is mechanical obstruction of the device secondary to pump thrombosis or mechanical outflow cannula obstruction. We describe a case of outflow cannula obstruction caused by kinking and twisting of the outflow graft after surgical manipulation of the pump. (Level of Difficulty: Beginner.).
RESUMEN
Treatment of cardiac sarcoidosis is challenging, as the disease can be refractory to traditional treatment with steroids. Infliximab, a tumor necrosis factor-α inhibitor, has been reportedly used in cardiac sarcoidosis, but published evidence is limited. The potential cardiotoxicity of infliximab and the Food and Drug Administration black-box warning for patients with heart failure have hindered the use of this agent in cardiac sarcoidosis. Here, we report a case of refractory cardiac sarcoidosis successfully treated with infliximab and discuss the important role of fluorine-18-fluorodeoxyglucose positron emission tomography in prognostication and guidance of therapy. (Level of Difficulty: Intermediate.).
Asunto(s)
Antineoplásicos/efectos adversos , Miocarditis/inducido químicamente , Miositis/inducido químicamente , Inhibidores de Proteínas Quinasas/efectos adversos , Choque Cardiogénico/inducido químicamente , Sorafenib/efectos adversos , Enfermedad Aguda , Biopsia , Cardiotoxicidad , Angiografía Coronaria , Ecocardiografía , Femenino , Humanos , Persona de Mediana Edad , Miocarditis/diagnóstico , Miocarditis/terapia , Miocardio/patología , Miositis/diagnóstico , Miositis/terapia , Choque Cardiogénico/diagnóstico , Choque Cardiogénico/terapiaAsunto(s)
Cardiomiopatías/diagnóstico por imagen , Granulomatosis con Poliangitis/diagnóstico por imagen , Inmunosupresores/uso terapéutico , Imagen Multimodal/métodos , Volumen Sistólico/fisiología , Agotamiento Psicológico , Cardiomiopatías/complicaciones , Cardiomiopatías/fisiopatología , Ecocardiografía/métodos , Estudios de Seguimiento , Granulomatosis con Poliangitis/complicaciones , Granulomatosis con Poliangitis/tratamiento farmacológico , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/etiología , Humanos , Imagen por Resonancia Cinemagnética/métodos , Masculino , Persona de Mediana Edad , Enfermedades Raras , Factores de TiempoRESUMEN
INTRODUCTION: In this PCI era, non-invasive management for patients presenting with non-ST elevation acute coronary syndrome continues to be relevant in several clinical circumstances. The duration of anticoagulation in non-invasively treated group is not clear. The use of heparin can be associated with fatal side effects. Thus, defining the optimal duration of therapy has significant implications for patient safety and cost. METHODS: Literature search was conducted using Medline (PubMed and Ovid SP), Embase, Cochrane Central Register of Controlled Clinical Trials (CENTRAL) and Cochrane Database of Systematic Review (CDSR) from the inception of these databases till present (August 2013). Only studies on humans and in English language were included. We included only published clinical trials which used UFH or LMWH as the anticoagulation agent. RESULTS: Initial search revealed 548 studies with 182 meeting inclusion criteria for full review. The duration of therapy was reported in 20 of 182 studies with an average treatment duration of 2-8 days. There was a trend towards increased bleeding without significant improvement in cardiovascular outcomes when anticoagulation was continued for more than 5-7 days. No single trial directly analyzed the composite end point outcome or adverse events in correlation with the duration of anticoagulation. CONCLUSION: There is a lack of good quality evidence to define the optimal duration of anticoagulation in the management of NSTE ACS. Well-designed, methodologically rigorous database studies are required to determine the shortest duration of therapy which achieves the benefits of anticoagulants while minimizing the costs and risks associated with prolonged anticoagulant use.
Asunto(s)
Síndrome Coronario Agudo/tratamiento farmacológico , Anticoagulantes/uso terapéutico , Coagulación Sanguínea/efectos de los fármacos , Heparina de Bajo-Peso-Molecular/uso terapéutico , Síndrome Coronario Agudo/diagnóstico , Síndrome Coronario Agudo/epidemiología , Anticoagulantes/efectos adversos , Anticoagulantes/farmacología , Coagulación Sanguínea/fisiología , Ensayos Clínicos como Asunto/métodos , Hemorragia/epidemiología , Hemorragia/prevención & control , Heparina/efectos adversos , Heparina/farmacología , Heparina/uso terapéutico , Heparina de Bajo-Peso-Molecular/efectos adversos , Heparina de Bajo-Peso-Molecular/farmacología , HumanosRESUMEN
The aim of the study was to compare the efficacy of revascularization versus medical therapy in patients with atherosclerotic renal artery stenosis (ARAS). ARAS is the most common cause of secondary hypertension and is associated with several complications, such as renal failure, coronary artery disease, cardiac destabilization, and stroke. Medical therapy is the cornerstone for management of ARAS; however, numerous trials have compared medical therapy with revascularization in the form of percutaneous renal artery angioplasty (PTRA) or percutaneous renal artery angioplasty with stent placement (PTRAS). Medline (PubMed and Ovid SP), Embase, Cochrane Central Register of Controlled Clinical Trials (CENTRAL), and Cochrane Database of Systematic Review (CDSR) were searched till present (November 2013) to identify clinical trials where medical therapy was compared with revascularization (PTRA or PTRAS). We performed a meta-analysis using a random effects model. The heterogeneity was assessed using I2 values. The initial database search identified 540 studies and 7 randomized controlled trials, and 2,139 patients were included in the final analysis. Angioplasty with or without stenting was not superior to medical therapy with respect to any outcome. The incidence of nonfatal myocardial infarction was 6.74% in both the stenting and medical therapy group (odds ratio=0.998, 95% confidence interval 0.698 to 1.427, p=0.992), and incidence of renal events in stenting population was found to be 19.58% versus 20.53% in medical therapy (odds ratio=0.945, 95% confidence interval 0.755 to 1.182, p=0.620). In conclusion, PTRA or PTRAS does not improve outcomes compared with medical therapy in patients with ARAS. Future studies should investigate to identify patient subgroups that may benefit from such an intervention.
Asunto(s)
Aterosclerosis , Fármacos Cardiovasculares/uso terapéutico , Obstrucción de la Arteria Renal , Procedimientos Quirúrgicos Vasculares/métodos , Animales , Aterosclerosis/complicaciones , Aterosclerosis/epidemiología , Aterosclerosis/terapia , Salud Global , Humanos , Morbilidad , Obstrucción de la Arteria Renal/epidemiología , Obstrucción de la Arteria Renal/etiología , Obstrucción de la Arteria Renal/terapia , Resultado del TratamientoRESUMEN
BACKGROUND AND OBJECTIVES: Anemia in cancer patients is common, but often under-recognized and under-treated. Erythropoiesis stimulating agents (ESAs) are widely used to prevent and treat cancer and chemo- therapy-related anemia, but recent studies suggest a negative impact on disease progression and survival associated with their use. This retrospective study describes the prevalence of anemia in cancer patients and recent trends in its management given the negative studies. PATIENTS AND METHODS: All consecutive adult cancer patients (n=959) admitted to regular medical units over one year were reviewed. Patients with a hemoglobin (Hb) value <12 g/dL on admission were considered anemic. Information on the primary tumor, main reasons for admission and treatment given were collected. RESULTS: At the time of enrollment, anemia was detected in 755 (78.7%) patients. The mean Hb value for anemic patients was 9.5 g/dL. Prevalence and severity of anemia varied according to tumor type and reason for admission. The majority (68.6%) of the anemic patients were not offered treatment. The mean Hb value at which treatment was started was 8.0 g/dL. Anemia treatment was related to its severity; treatment rates were 94.4%, 32.9%, and 5.0% in patients with severe, moderate and mild anemia, respectively (P<.0001). Blood transfusion was used the most while ESAs were rarely used. Length of hospital stay was affected by the presence of anemia (7.2 days in anemic patients vs. 4.85 days in nonanemic patients) (P<.001). CONCLUSIONS: Blood transfusion was used the most for cancer-related anemia, while ESAs were rarely used. The majority of patients with moderate anemia were not treated, including patients on active chemotherapy. Better guidelines addressing anemia management in this subgroup of patients are highly needed.